4:1 0 There was a significant association between education and

4:1.0. There was a significant association between education and patients’ adherence to their medications. Side effects of the anti-tuberculosis agents have negative impact on patients’ drug adherence. Positive effect of counseling on the patients’ adherence to their medication regimen was also recorded. Age had no significant relationship with patients’ drug adherence, whereas education was significantly associated with patients’ drug adherence. Drug adherence rate accounted for 94.6% of the patients seen over the period of study. The high rate of drug adherence observed was probably due to free anti-tuberculosis

drugs, free medical laboratory service and the rapid improvement in the signs and symptoms of the disease. Also, directly observed treatment short course (DOTs) currently introduced in the hospital coupled with free supply of tuberculosis resistant strain drugs to ACY-241 mw patients, improved adherence and impede tuberculosis transmission within the community, and thereby stem the tide of the disease.”
“The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility

fractures in post-menopausal women, as part of the Institute’s single technology appraisal (STA) process. The University of Aberdeen Health Technology Assessment Group were commissioned to act 17DMAG as the Evidence Src inhibitor Review Group (ERG); the role of the ERG being to appraise the manufacturer’s submission and to produce an independent report. This article provides a description of the company submission, the ERG review and NICE’s

subsequent decisions.

The manufacturer considered that denosumab would be appropriate for patients unable to take, comply with or tolerate oral bisphosphonates.

Comparator treatments selected for the submission were, therefore, ‘no treatment’, raloxifene, strontium ranelate, intravenous zoledronic acid, intravenous ibandronate and teriparatide. The main effectiveness evidence for denosumab was derived from a large randomized controlled trial comparing denosumab with placebo. Given by subcutaneous injection at 6-monthly intervals for 3 years, denosumab reduced the incidence of hip fracture by 40%, and reduced the incidence of clinical vertebral fracture by 69%. An indirect treatment comparison was used to derive adjusted relative risk (RR) estimates for different types of fracture for each comparator versus placebo. The RRs (95% CI) applied for denosumab were 0.316 (0.208, 0.478) for clinical vertebral fracture, 0.605 (0.373, 0.983) for hip fracture and 0.842 (0.638, 1.110) for wrist fracture. Despite a number of concerns surrounding the methodology of the indirect comparison, the ERG was satisfied with the robustness of the effect estimates.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>